This event has passed.

EU Healthcare Biotech Policy Priorities for SMEs

Name: EU Healthcare Biotech Policy Priorities for SMEs
Start: 2021-06-03T14:00:00+02:00
End: 2021-06-03T15:00:00+02:00

3 June 2021 @ 2:00 pm – 3:00 pm CEST

Join the EuropaBio Healthcare Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the ongoing revision of the basic pharmaceutical legislation and of regulations for medicines for rare and paediatric diseases, SMEs should be planning how they build and grow their businesses, whether within the EU or outside.

About the EuropaBio SME Platform

The SME platform is a community of SMEs across all sectors in Europe, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders.

EuropaBio

+32 2 735 03 13

View Organizer Website

Event Navigation

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.